Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2010
08/26/2010US20100215669 Anti-cd79b antibodies and immunoconjugates and methods of use
08/26/2010US20100215664 Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6 -mediated signalling
08/26/2010US20100215661 Nicotinamide derivates useful as p38 inhibitors
08/26/2010US20100215657 Methods and Compositions Using Klotho-FGF Fusion Polypeptides
08/26/2010US20100215656 Deletions in domain ii of pseudomonas exotoxin a that remove immunogenic epitopes
08/26/2010US20100215655 Angiogenesis-inhibiting chimeric proteins and the use
08/26/2010US20100215653 Methods of treating neoplastic, autoimmune and inflammatory diseases
08/26/2010US20100215652 Nicotinamide derivates useful as p38 inhibitors
08/26/2010US20100215651 Humanized antibodies that bind to CD19 and their uses
08/26/2010US20100215648 Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer
08/26/2010US20100215647 Immunological Compositions as Cancer Biomarkers and/or Therapeutics
08/26/2010US20100215646 Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segments
08/26/2010US20100215642 Synthetic rna-based agonists of tlr7
08/26/2010US20100215638 Method for treatment of prostate cancer and screening of patients benefiting from said method
08/26/2010US20100215637 Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
08/26/2010US20100215633 Method for feeding dairy cows and dairy goats supplements to increase the C2 hxroylated estrogen (C2) to C16 hydroxlated estrogen (C16) ratio secreted in their urine
08/26/2010US20100215629 Treatment of tumors using t lymphocyte preparations
08/26/2010US20100215628 Method for preparing cell populations with anti-tumor immune response activity
08/26/2010US20100215621 Recombinant Adenoviruses Capable Of Regulating Angiogenesis
08/26/2010US20100215620 The co-culture method of sphingomonas sp. bacterial strain and aspergillus sp. fungus strain, new anti-cancer and antibiotic glionitrins derived from this co-culture method, and pharmaceutical composition containing glionitrins or pharmaceutically acceptable salt thereof as an active ingredient
08/26/2010US20100215615 Immunocytokines for cancer treatment in combination with chemotherapeutic agents
08/26/2010US20100215614 Enterostatin as Inhibitor of Angiogenesis
08/26/2010US20100215583 Cell nucleus-entering compositions
08/26/2010US20100215582 Liposome and method for producing liposome
08/26/2010US20100215578 Catalytic Radiofluorination
08/26/2010US20100215577 Compositions and methods for visualizing and eliminating cancer stem cells
08/26/2010US20100215576 Diagnosis and treatment of neuroectodermal tumors
08/26/2010US20100215575 Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
08/26/2010US20100215574 Process for producing an injectable medicament preparation
08/26/2010US20100215573 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
08/26/2010US20100215572 Methods of treatment using ldcam
08/26/2010US20100215571 Polymer based radionuclide containing particulate material
08/26/2010DE102009010489A1 Dissolving pathogenic body parts e.g. tumors, debris or parasites, comprises directly injecting once and/or many times and/or cell-dissolving substance (e.g. acid) into cells or cell complexes to be removed (e.g. tumor) using e.g. catheter
08/26/2010CA2786891A1 Immunopotentiating composition and process for producing same
08/26/2010CA2753698A1 Methods and compositions for inhibiting cellular proliferation and surgical adhesion
08/26/2010CA2753294A1 Proproteins and methods of use thereof
08/26/2010CA2753280A1 Anti-human .alpha.9 integrin antibody and use thereof
08/26/2010CA2753010A1 Pyridocarbazole type compounds and applications thereof
08/26/2010CA2752603A1 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
08/26/2010CA2752584A1 Specific binding proteins and uses thereof
08/26/2010CA2752560A1 Foxm1 peptides and vaccines containing the same
08/26/2010CA2752527A1 Indole/benzimidazole compounds as mtor kinase inhibitors
08/26/2010CA2752510A1 Methods and kits for diagnosis of cancer and prediction of therapeutic value
08/26/2010CA2752373A1 Glutathione-based drug delivery system
08/26/2010CA2752265A1 Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
08/26/2010CA2751767A1 3,3'-spiroindolinone derivatives as anticancer agents
08/26/2010CA2750993A1 Carboxamide compounds and their use as calpain inhibitors
08/26/2010CA2729593A1 B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer
08/25/2010EP2221377A1 Oligonucleotide compositions with enhanced efficiency
08/25/2010EP2221374A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
08/25/2010EP2221308A1 Benzazepinone compound
08/25/2010EP2221089A1 Lipoxin analogs as novel inhibitors of angiogenesis
08/25/2010EP2221062A1 Novel adjuvant
08/25/2010EP2221060A1 Use of specific peptides in the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM)
08/25/2010EP2221053A1 Pharmaceutical composition comprising protein methyltransferase I inhibitors and its use for treating tumour diseases
08/25/2010EP2220122A2 Humanized antibodies against tl1a
08/25/2010EP2220119A2 Anti-igf antibodies that bind to igf-1 and igf-2 but not to insulin
08/25/2010EP2220114A1 Anti-vegf antibodies
08/25/2010EP2220092A1 Azaindolizines and methods of use
08/25/2010EP2220088A2 New smac mimetic compounds as apoptosis inducers
08/25/2010EP2220078A2 Benzomorpholine derivatives and methods of use
08/25/2010EP2220072A2 Polymorphs of sunitinib base and processes for preparation thereof
08/25/2010EP2220071A2 Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
08/25/2010EP2220070A1 2-benzylpyridazinone derivatives as met kinase inhibitors
08/25/2010EP2220069A1 Methods for identification of jak kinase interacting molecules and for the purification of jak kinases
08/25/2010EP2220068A1 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
08/25/2010EP2220066A1 Benzofuran anilide histone deacetylase inhibitors
08/25/2010EP2220061A1 Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
08/25/2010EP2220054A2 Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
08/25/2010EP2220051A1 Pyridazine derivatives useful as fungicides and for the treatment of cancer
08/25/2010EP2220050A2 Diarylhydantoin compounds as androgen receptor modulators
08/25/2010EP2220047A2 Compounds and methods
08/25/2010EP2220042A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
08/25/2010EP2220028A1 Halogenated analogues of anti-fibrotic agents
08/25/2010EP2219683A2 Targeted radiotherapy
08/25/2010EP2219672A1 Anti-vegf antibody compositions and methods
08/25/2010EP2219651A1 Oral compositions of abt-263 for treating cancer
08/25/2010EP2219629A1 Novel compounds as cannabinoid receptor ligands
08/25/2010EP2219616A2 Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same
08/25/2010EP2051981B1 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors
08/25/2010EP2047855B1 Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants)
08/25/2010EP2032562B1 Selective inhibitors of rock protein kinase and uses thereof
08/25/2010EP1994030B1 Multi-cyclic compounds and method of use
08/25/2010EP1931641B1 NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI
08/25/2010EP1648465B1 Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
08/25/2010EP1641792B1 Pyrrolodihydroisoquinolines as pde10 inhibitors
08/25/2010EP1469882B1 Treatment of nervous system diseases with goat serum
08/25/2010EP1404367B1 Use of polyclonal anti-hiv goat serum as a therapeutic agent
08/25/2010EP1363632B1 Receptor selective cannabimimetic aminoalkylindoles
08/25/2010EP1339402B1 Azaphenanthridone derivatives and their use as parp inhibitors
08/25/2010EP1263722B1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
08/25/2010EP1263721B1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
08/25/2010EP1228208B1 36p6d5: secreted tumor antigen
08/25/2010EP1181047B9 Composition comprising alkaline sphingomyelinase of bacterial origin for use as a dietetic preparation, food supplement or pharmaceutical product
08/25/2010CN1978448B 10-hydroxy camptothecin arginine salt, and its preparing method and use
08/25/2010CN1977972B Anti tumour drug oral colon targeting preparation and its preparing method
08/25/2010CN1972955B Radiosensitizer
08/25/2010CN1972917B Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
08/25/2010CN1969876B Lyophilized injection of lentinan and preparation process thereof
08/25/2010CN1915432B Gene medication in use for treating tumor from epithelium, and preparation method
1 ... 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 ... 2211